Noveome Biotherapeutics Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$36.2M
- Investors
-
10
Noveome Biotherapeutics General Information
Description
Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues. The company's products contain numerous biologic components at physiologic concentrations which function in combination and synergistically to yield anti-inflammatory, neuroprotective, anti-apoptotic, and vascular integrity preservative activities, enabling healthcare providers to provide treatment of complex diseases.
Contact Information
Website
www.noveome.comCorporate Office
- 100 Technology Drive
- Suite 200
- Pittsburgh, PA 15219
- United States
Corporate Office
- 100 Technology Drive
- Suite 200
- Pittsburgh, PA 15219
- United States
Noveome Biotherapeutics Timeline
Noveome Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series E) | 08-Aug-2024 | $36.2M | Completed | Clinical Trials - Phase 2 | ||
| 11. Later Stage VC (Series D1) | 01-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC | 02-Oct-2020 | Completed | Clinical Trials - Phase 2 | |||
| 9. Grant | 07-May-2020 | Completed | Clinical Trials - Phase 2 | |||
| 8. Debt - PPP | 11-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series D) | 09-Apr-2019 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series C) | 14-Apr-2016 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 08-Jul-2015 | Completed | Startup | |||
| 4. Later Stage VC (Series B) | $6M | $9.1M | Completed | Startup | ||
| 3. Grant | 01-Jan-2006 | $148K | $3.1M | Completed | Startup |
Noveome Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 22,000,000 | $0.001000 | 7% | $0.28 | $0.28 | 1x | $0.28 | 11% |
| Series A | 31,000,000 | $0.001000 | 7% | $0.1 | $0.1 | 1x | $0.1 | 15.5% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Noveome Biotherapeutics Comparisons
Industry
Financing
Details
Noveome Biotherapeutics Competitors (39)
One of Noveome Biotherapeutics’s 39 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| CalciMedica | Formerly VC-backed | La Jolla, CA | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA |
Noveome Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Noveome Biotherapeutics Patents
Noveome Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4243838-A1 | Secretome fractions and uses thereof | Pending | 16-Nov-2020 | ||
| US-20240066071-A1 | Secretome fractions and uses thereof | Pending | 16-Nov-2020 | ||
| EP-4243838-A4 | Secretome fractions and uses thereof | Pending | 16-Nov-2020 | ||
| EP-4121056-A1 | Use of st266 to treat severe systemic inflammation and post-acute covid-19 syndrome | Pending | 19-Mar-2020 | ||
| US-20210290728-A1 | Use of st266 to treat severe systemic inflammation and post-acute covid-19 syndrome | Pending | 19-Mar-2020 | A61P29/00 |
Noveome Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Noveome Biotherapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MAK Capital | Hedge Fund | Minority | ||
| Lancet Capital | Venture Capital | Minority | ||
| Miraki Innovation | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Commonwealth of Pennsylvania | Government |
Noveome Biotherapeutics FAQs
-
When was Noveome Biotherapeutics founded?
Noveome Biotherapeutics was founded in 2000.
-
Where is Noveome Biotherapeutics headquartered?
Noveome Biotherapeutics is headquartered in Pittsburgh, PA.
-
What is the size of Noveome Biotherapeutics?
Noveome Biotherapeutics has 25 total employees.
-
What industry is Noveome Biotherapeutics in?
Noveome Biotherapeutics’s primary industry is Biotechnology.
-
Is Noveome Biotherapeutics a private or public company?
Noveome Biotherapeutics is a Private company.
-
What is Noveome Biotherapeutics’s current revenue?
The current revenue for Noveome Biotherapeutics is .
-
How much funding has Noveome Biotherapeutics raised over time?
Noveome Biotherapeutics has raised $63.9M.
-
Who are Noveome Biotherapeutics’s investors?
MAK Capital, Lancet Capital, Miraki Innovation, , and Commonwealth of Pennsylvania are 5 of 10 investors who have invested in Noveome Biotherapeutics.
-
Who are Noveome Biotherapeutics’s competitors?
Cristal Therapeutics, CalciMedica, Eligo Bioscience, Meditope Biosciences, and NGM Biopharmaceuticals are some of the 39 competitors of Noveome Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
